STOCK TITAN

Citadel Entities and Kenneth Griffin Report 5.1% Ownership in SMLR

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Citadel-related entities and Kenneth Griffin report beneficial ownership of Semler Scientific (SMLR) common stock totaling approximately 697,427 shares, representing 5.1% of the class. The filing is a joint Schedule 13G covering Citadel Securities GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin. Ownership totals per entity range from 570 shares to 697,997 shares for Mr. Griffin. The groups report no sole voting or dispositive power; all reported voting and dispositive power is shared. The percentages are calculated on 13,688,405 shares outstanding as of June 30, 2025.

Positive

  • Material institutional disclosure: Citadel-related reporting persons disclose a combined 5.1% stake, meeting SEC transparency thresholds
  • Clarity on holdings: Filing provides exact share counts and the share-outstanding basis (13,688,405) used to calculate percentages

Negative

  • No sole voting or dispositive power: All reported authority is shared, indicating limited unilateral governance influence
  • Passive filing (13G): The statement indicates holdings are reported as passive rather than an active intent to change control

Insights

TL;DR: Citadel-linked parties disclose a >5% passive stake in SMLR, indicating a notable institutional position without sole control.

The joint Schedule 13G shows institutional accumulation equivalent to 5.1% of Semler Scientific's outstanding common stock. For investors, a >5% passive filing signals that sizeable liquidity and trading flows may be associated with these desks and funds. The filing discloses shared voting and dispositive power rather than sole control, consistent with passive or investment-management positions rather than an activist intent. The base of 13,688,405 shares outstanding provides the context for the 5.1% figure. This is material ownership disclosure but does not change governance dynamics given the lack of sole control.

TL;DR: Ownership crosses the 5% disclosure threshold but shows no unilateral control; governance impact appears limited.

The Schedule 13G identifies multiple affiliated reporting persons and shows shared voting and dispositive power across Citadel entities and Mr. Griffin. Because the filing is a 13G rather than a 13D and indicates shared rather than sole authority, it reflects a passive or investment-management position rather than a coordinated effort to influence corporate control. From a governance standpoint, this means Semler Scientific should note the institutional holder but does not face an immediate change in control or activist pressure based on this filing alone.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 13,688,405 Shares outstanding as of June 30, 2025 (according to the issuer's Form 8-K as filed with the Securities and Exchange Commission on August 4, 2025).


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:08/14/2025

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

FAQ

How many SMLR shares do Citadel entities and Kenneth Griffin report owning?

The filing reports 697,427 shares (5.1% of class) for certain Citadel entities and 697,997 shares (5.1%) for Kenneth Griffin, based on 13,688,405 shares outstanding as of June 30, 2025.

Does this Schedule 13G indicate an attempt to control Semler Scientific (SMLR)?

No. The filing is a Schedule 13G and reports shared voting and dispositive power, indicating a passive investment rather than an effort to change or influence control.

Which Citadel entities filed this Schedule 13G for SMLR?

The reporting persons are Citadel Securities GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin.

What voting and disposition powers are reported in the filing?

All reporting persons report 0 sole voting and dispositive power and instead report shared voting and shared dispositive power for the disclosed shares.

What share count was used to calculate the ownership percentages?

The percentages are based on 13,688,405 shares outstanding as of June 30, 2025, per the filing.
Semler Scientific Inc

NASDAQ:SMLR

SMLR Rankings

SMLR Latest News

SMLR Latest SEC Filings

SMLR Stock Data

310.75M
13.43M
11.96%
70.82%
16.91%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
CAMPBELL